MICA expression predicts the efficacy of postoperative chemotherapy combined with NK cell infusion in non-small cell lung cancer

ZHOU Zhifeng; LI Jieyu; LIN Wansong; CHEN Shuping; WANG Ling; YE Yunbin; ZHENG Qingfeng

doi:10.13431/j.cnki.immunol.j.20170139

Abstract：This study was designed to investigate whether MICA expression can predict the efficacy of postoperative chemotherapy combined with NK cell infusion in non-small cell lung cancer (NSCLC).MICA expression in 92 cases lung cancer tissue was evaluated by Flow cytometry,in which 41 patients received adjuvant chemotherapy alone (Docetaxel + Cisplatin) and 51 patients received adjuvant chemotherapy combined with autologous NK cell therapy.Factors associated with survival of patients with non-small cell lung cancer were subjected to univariate and multivariate analysis.Data showed that MICA negative expression of non-small cell lung cancer was 46.74％ while MICA positive expression was 53.26％;NKG2D was up to (97.8％±2.5)％ after NK cell culture for 14-17 days,which was significantly higher than before culture (88.2％ ± 7.2)％ (P＜0.05).MICA expression was not significantly related to NKG2D (P=0.189).The 3-year and 5-year survival rates of patients with non-small cell lung cancer at stage Ⅱ were 70.8％ and 47.9％;the 3-year and 5-year survival rates of patients at stage Ⅲ A were 54.5％ and 22.7％.Median overall survival (mOS) was significantly different in patients treated with or without NK (P=0.037),and in patients with different clinical stages (TNM) (P=0.009),but the mOS showed no correlation with age (P=0.999),gender (P=0.412),pathological type (P=0.782) and MICA expression (P=0.172).Multivariate analysis indicated that NK therapy (P=0.172),and the stage (P=0.002) and the interaction of MICA status and NK therapy (P=0.002) were independent prognostic factors for mOS.Taken together,MICA plays an important role in postoperative chemotherapy combined with NK cell immunotherapy in patients with non-small cell lung cancer,and MICA expression is a good prognostic factor for NK cell immunotherapy.